High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Investing.com -- Analysts at Leerink Partners upgraded Johnson & Johnson from “Market Perform” to “Outperform,” citing accelerating growth prospects driven by a wave of new drug launches and expanding oncology and immunology franchises. The brokerage also raised its 12-month price target to $265 from $252, implying roughly 18% upside from the stock’s recent close.
AMD, Under Armour downgraded: Wall Street's top analyst calls
The SPDR Russell 1000 Yield Focus ETF (NYSEARCA:ONEY) harvests income from large-cap American stocks by screening the Russell 1000 for companies combining high yield with quality and low financial risk. With ONEY trading near $125 and up about 20% over the past year, the question for holders is whether the distributions backing that performance are ... Russell 1000 Dividend ETF Hits $125 as Johnson & Johnson Leads The Safety Test
S&P Global rates only two U.S. public companies AAA, one notch above the federal government itself. S&P downgraded the United States to AA+ in 2011, and Fitch followed in 2023, leaving Uncle Sam a step below the small club still graded at the top of the scale. That club has two members: Johnson & Johnson ... The 2 US Companies With a Better Credit Rating Than Uncle Sam Belong in Every Retirement Portfolio
Pre-Market Stock Futures: Futures are trading mixed on Wednesday, after a rough day for technology stocks and the Nasdaq. The combination of the prospect of a longer struggle with Iran, and higher inflation, which soared to 3.8% annually, the highest since May 2023, while the core number, which is less food and energy, rose to ... Here Are Wednesday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Akamai Technologies, HEICO, Johnson & Johnson, MasTec, MercadoLibre, Sandisk, Snap
The latest generation of the coronary intravascular lithotripsy device is designed to be more flexible to help physicians navigate tight arteries to break up calcified deposits and restore blood flow.
Johnson & Johnson (NYSE:JNJ) has launched the Shockwave C2 Aero Coronary IVL Catheter for calcified coronary artery disease, adding to its intravascular lithotripsy portfolio. The company reported key clinical results for TREMFYA in perianal fistulizing Crohn’s disease, the first major trial in this setting in roughly 20 years. JNJ-4804 produced positive data in highly refractory inflammatory bowel disease patients, pointing to potential options in difficult to treat cases. The OTTAVA...
US stocks (^DJI, ^IXIC, ^GSPC) are mixed ahead of Tuesday's market close as the Nasdaq Composite drops by over 1%, pushed lower by declines in chip stocks. Yahoo Finance Markets and Data Editor Jared Blikre takes a closer look at the market reaction to the April Consumer Price Index (CPI) report released this morning.
JNJ bets on Tremfya and newly approved Icotyde to drive immunology growth as Stelara faces biosimilar pressure.
HALO beats Q1 earnings estimates as royalty revenues from partner drugs and strong product sales lift revenues by 42% year over year.
BAYRY beats Q1 earnings estimates as Crop Science sales rise, while Nubeqa and Kerendia gains help offset declines in Xarelto and Eylea.
JPMorgan Equity Premium Income ETF (NYSEARCA:JEPI) and JPMorgan Nasdaq Equity Premium Income ETF (NYSEARCA:JEPQ) pull from very different stock universes. JEPI leans on S&P 500 names with a covered call overlay. JEPQ runs the same income playbook on the Nasdaq-100. The latest fact sheets show why that distinction matters in 2026. Defensive Blue Chips Anchor ... Why JPMorgan Equity Premium Income ETF Limits Upside While JPMorgan Nasdaq Equity Premium Income ETF Sacrifices Growth for 11.98% Yields
Recent performance snapshot for Johnson & Johnson (JNJ) Johnson & Johnson (JNJ) has held relatively steady in the very short term, with the stock roughly flat over the past day but down about 1% over the past week and 7% over the past month. Over the past 3 months the share price is also down about 7%, even as the stock shows a total return of about 48% over the past year and around 50% across the past 3 and 5 years. See our latest analysis for Johnson & Johnson. The recent 7% decline in the...
We recently compiled a list of the 10 Best Cancer Stocks to Buy for the Long Term. Johnson & Johnson is among the best cancer stocks. TheFly reported on May 5 that JNJ released Phase 3 FUZION study results evaluating TREMFYA in adults with active perianal fistulizing Crohn’s disease. At 24 weeks, the therapy showed […]
Merck falls 7% despite an earnings beat as a pipeline setback and Gardasil weakness act as dampeners. However, Keytruda and new launches support growth.
The Goldman Sachs Retirement Survey 2025 captures a tension that runs through the entire retirement landscape. A full 68% of working respondents say they are confident they will meet their retirement goals. At the same time, 58% believe they will outlive their savings. Goldman calls this the Optimism Gap, a split between how workers feel ... Goldman Sachs Retirement Survey 2025: 58% of Americans Expect to Outlive Their Savings, and the Income Strategy That Changes the Math
The Goldman Sachs Retirement Survey & Insights Report 2025 puts a hard number on what many workers already sense: the bar for retirement keeps moving higher. The estimated total cost of retirement for a unisex retiree is projected to reach $2,569,000 by 2043, up from $1,747,000 in 2033. That climb reflects two forces working together. ... Goldman Sachs Retirement Survey 2025: Retirement Could Cost $2.5 Million by 2043, and Most Americans Are Not Saving Fast Enough to Keep Up
Markets are on the rise, but worries about a recession remain elevated as May gets underway.
A full-time federal minimum wage worker in the United States earns $7.25 an hour, or about $15,080 a year before taxes, working 40 hours a week for 52 weeks. The question for anyone with capital: what does it take to clear that bar without having to ask anyone, “Do you want fries with that?” On ... A $500,000 Dividend Portfolio That Pays More Than a Full-Time Minimum Wage Job
From AI-accelerated drug discovery to a $55 billion domestic manufacturing push, the U.S. health innovation engine is just getting started.
A new Nationwide Retirement Institute survey paints a stark picture: most Americans approaching retirement do not actually understand the program they are banking on. Only 21% of respondents correctly identified their full retirement age based on their year of birth, and the average adult answered just 8 of 15 true-or-false questions about Social Security correctly. ... The Nationwide Social Security Survey Says Most Americans Are Flying Blind on Benefits, Here’s the Income Strategy That Fills t
The fear is loud, and the data backs it up. According to the Nationwide Retirement Institute’s 2025 Social Security Survey, 83% of Americans currently receiving or expecting to receive Social Security are concerned about the program’s future. That worry is not happening in a vacuum. The Social Security Administration’s own trustees project that the Old-Age ... Nationwide Survey: 83% of Americans Are Worried Social Security Won’t Survive, and Here’s What to Do About It
These companies pay some of the world's most bankable dividends.
Warren Buffett stepped down as CEO of Berkshire Hathaway (BRK-B) on December 31, 2025, after six decades leading the conglomerate he transformed from a struggling textile mill into a $1 trillion empire. The “Oracle of Omaha” left his successor, Greg Abel, with a very concentrated portfolio: more than 65% of Berkshire’s $381 billion portfolio is ... Warren Buffett and Berkshire Hathaway Own 2 Dividend Kings That Will Never Be Sold
Investing.com -- Genmab reported a 25% year-on-year increase in first-quarter revenue for 2026, driven by strong royalty income from blockbuster cancer drug DARZALEX and multiple sclerosis treatment Kesimpta, as the Danish biotech company continued investing heavily in its late-stage oncology pipeline.
Johnson & Johnson (NYSE:JNJ) has launched its global "Generation Fine" campaign to address depression care and improve patient conversations. The company reported new FDA approvals and positive Phase 3 data in immunology and neuropsychiatry, alongside progress on its OTTAVA robotic surgery platform. JNJ outlined an accelerated global registration plan for JNJ-1900 in head and neck cancer. The dual target antibody JNJ-4804 for inflammatory bowel disease did not meet its main Phase 2b...
Darzalex and new launches fuel J&J's 17.8% oncology sales growth in Q1 as the company targets $50B in cancer sales by 2030.
Michael Barclay, lead manager of the Columbia Dividend Income fund, favors dividend growers over high yields.
Deal volume in 2026 is far outpacing last year, and is being driven by cancer and autoimmune disease drugs.
They have combined for 118 years of consecutive dividend increases.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.